NCT05028660View on ClinicalTrials.gov

AURORAX-0093A: Glycosaminoglycan Profiling for Prognostication of Muscle-invasive Bladder Cancer - a Pilot Study

CompletedOBSERVATIONAL
Enrollment

43

Participants

Timeline

Start Date

July 21, 2021

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Muscle-Invasive Bladder Carcinoma
Interventions
DIAGNOSTIC_TEST

GAG score

blood and urine samples to determine GAG scores

Trial Locations (5)

Unknown

Zealand University Hospital, Roskilde

AOU Careggi, Florence

IRCCS Ospedale San Raffaele, San Raffaele Hospital, Milan

IRCCS Regina Elena, Rome

Sahlgrenska University Hospital, Gothenburg

Sponsors

Lead Sponsor

Elypta
All Listed Sponsors
collaborator

Lund University

OTHER

lead

Elypta

INDUSTRY

NCT05028660 - AURORAX-0093A: Glycosaminoglycan Profiling for Prognostication of Muscle-invasive Bladder Cancer - a Pilot Study | Biotech Hunter | Biotech Hunter